Press Releases

pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema WATERTOWN, Mass.--(BUSINESS WIRE)--May. 7, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment

pSivida Corp Announces Third Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass.--(BUSINESS WIRE)--May. 3, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. Announces ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema WATERTOWN, Mass., Apr 24, 2012 (BUSINESS WIRE) --pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment

pSivida Announces Second Tech Evaluation Agreement with its BioErodible Durasert Technology WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 13, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today

pSivida Corp. Names Douglas Godshall to Board of Directors WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 6, 2012-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected

• ILUVIEN® expected to be the first sustained release pharmaceutical in the European Union (EU) to treat diabetic macular edema (DME)
• ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011 WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 8, 2012-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced

pSivida CEO to Present at 14th Annual BioCEO & Investor Conference February 14 WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 6, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that

pSivida CEO to Participate in Panel at Glaucoma 360 Conference February 3 WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 2, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its

pSivida Corp Announces Second Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 1, 2012-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Announces Tech Evaluation Agreement with Leading Pharmaceutical Company WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 22, 2011-- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that

pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN(R) for DME and pSivida's Product Pipeline WATERTOWN, Mass., Nov 11, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products

pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(R) for DME WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 11, 2011-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

pSivida Corp. Reports Results for the First Quarter Ended September 30, 2011 WATERTOWN, Mass., Nov 07, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced

pSivida Corp. Announces First Quarter 2012 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Oct 31, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye

Second Consecutive Year Company Achieves Ranking

pSivida Corp. Reports Fourth Quarter and Fiscal Year 2011 Results WATERTOWN, Mass., Sep 12, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including clinical stage product

pSivida Announces Opening of Investigator-Sponsored Trial for Injectable, Sustained Release FAc Insert for Posterior Uveitis WATERTOWN, Mass., Sep 12, 2011 (BUSINESS WIRE) -- Drug delivery company pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) today announced the opening of an investigational new drug

pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference BOSTON, Sep 09, 2011 (BUSINESS WIRE) -- pSivida Corp, (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it

pSivida Corp Announces Fourth Quarter and Fiscal Year 2011 Financial Results Release Date and Conference Call Information WATERTOWN, Mass., Sep 06, 2011 (BUSINESS WIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of